

Kirsten C Morley

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2811024/kirsten-c-morley-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

84
papers

1,726
citations

24
h-index

39
g-index

89
ext. papers

2,041
ext. citations

4.2
avg, IF

4.83
L-index

#	Paper	IF	Citations
84	Sex as a Potential Moderator for Baclofen Response in the Treatment of Alcohol Dependence.. <i>Frontiers in Global Women S Health</i> , 2022 , 3, 807269	8.4	1
83	A pilot study of a text message and online brief contact intervention following self-harm or a suicide attempt: A mixed methods evaluation.. <i>General Hospital Psychiatry</i> , 2022 , 76, 1-2	5.6	0
82	The evaluation of the role of technology in the pathways to comorbidity care implementation project to improve management of comorbid substance use and mental disorders.. <i>Journal of Multimorbidity and Comorbidity</i> , 2022 , 12, 26335565221096977		0
81	Implementation of a Multi-Modal Training Program for the Management of Comorbid Mental Disorders in Drug and Alcohol Settings: Pathways to Comorbidity Care (PCC). <i>Journal of Dual Diagnosis</i> , 2021 , 17, 304-312	2.4	0
80	New Australian guidelines for the treatment of alcohol problems: an overview of recommendations. <i>Medical Journal of Australia</i> , 2021 , 215 Suppl 7, S3-S32	4	5
79	GABAB Receptors and Alcohol Use Disorders: Clinical Studies. <i>Current Topics in Behavioral Neurosciences</i> , 2021 , 1	3.4	3
78	New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1291-1303	4	8
77	Commentary on Donoghue: Low prescribing rates of pharmacotherapy for alcohol use disorder limit potential public health impact. <i>Addiction</i> , 2021 , 116, 3027-3028	4.6	2
76	High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: Preliminary findings from a pharmaco-fMRI study. <i>European Neuropsychopharmacology</i> , 2021 , 46, 28-36	1.2	3
75	Are bottle shops using Twitter to increase advertising or encourage drinking during COVID-19?. <i>Australian and New Zealand Journal of Public Health</i> , 2021 , 45, 391-393	2.3	
74	Online interventions for people hospitalized for deliberate self-harm and problematic alcohol use: Lessons learned from the iiAIM trial. <i>Bulletin of the Menninger Clinic</i> , 2021 , 85, 123-142	1.3	1
73	Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. <i>Psychopharmacology</i> , 2021 , 238, 1291-1302	4.7	12
72	Psychosocial Interventions for Reducing Suicidal Behaviour and Alcohol Consumption in Patients With Alcohol Problems: A Systematic Review of Randomized Controlled Trials. <i>Alcohol and Alcoholism</i> , 2021 , 56, 17-27	3.5	4
71	A Content Analysis of Reddit UsersTPerspectives on Reasons for Not Following Through with a Suicide Attempt. <i>Cyberpsychology, Behavior, and Social Networking</i> , 2021 , 24, 642-647	4.4	2
70	A systematic review of evidence-based practice implementation in drug and alcohol settings: applying the consolidated framework for implementation research framework. <i>Implementation Science</i> , 2021 , 16, 22	8.4	2
69	Assessing the validity of the Wechsler Adult Intelligence Scale (WAIS-IV) in predicting completion in a long-term residential rehabilitation for substance use problems. <i>Applied Neuropsychology Adult</i> , 2021 , 1-6	1.9	0
68	The role of clinical supervision in implementing evidence-based practice for managing comorbidity. <i>Clinical Supervisor, The</i> , 2021 , 40, 158-177	1.3	2

67	Drinking risk varies within and between Australian Aboriginal and Torres Strait Islander samples: a meta-analysis to identify sources of heterogeneity. <i>Addiction</i> , 2020 , 115, 1817-1830	4.6	14
66	Implementation of evidence-based practice for alcohol and substance use disorders: protocol for systematic review. <i>Systematic Reviews</i> , 2020 , 9, 25	3	10
65	Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. <i>Human Psychopharmacology</i> , 2020 , 35, e2722	2.3	3
64	Brain N-Acetyl Aspartate and associations with cognitive impairment in alcohol dependent patients. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2020 , 42, 111-117	2.1	3
63	The role of clinical champions in facilitating the use of evidence-based practice in drug and alcohol and mental health settings: A systematic review. <i>Implementation Research and Practice</i> , 2020 , 1, 263348952095907	3.3	8
62	Alcohol use disorder and circulating cytokines: A systematic review and meta-analysis. <i>Brain, Behavior, and Immunity</i> , 2020 , 89, 501-512	16.6	13
61	Evidence based models of care for the treatment of alcohol use disorder in primary health care settings: a systematic review. <i>BMC Family Practice</i> , 2020 , 21, 260	2.6	2
60	Genetic Polymorphisms on , and in Young Adults: Lack of Association With Alcohol Consumption. <i>Frontiers in Psychiatry</i> , 2020 , 11, 549429	5	2
59	Brain GABA levels are reduced in alcoholic liver disease: A proton magnetic resonance spectroscopy study. <i>Addiction Biology</i> , 2020 , 25, e12702	4.6	3
58	A pilot study of escape, avoidance, and approach behaviors in treated alcohol-dependent males. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2019 , 41, 601-614	2.1	2
57	Insomnia and excessive daytime sleepiness in women and men receiving methadone and buprenorphine maintenance treatment. <i>Substance Use and Misuse</i> , 2019 , 54, 1589-1598	2.2	10
56	Prevalence and Risk Factors of Emergency Department Presentations with Methamphetamine Intoxication or Dependence: A Systematic Review and Meta-analysis. <i>Issues in Mental Health Nursing</i> , 2019 , 40, 567-578	1.5	5
55	Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial. <i>Alcohol and Alcoholism</i> , 2019 , 54, 272-278	3.5	5
54	Systematic Reviews of Mindfulness and Acceptance and Commitment Therapy for Alcohol Use Disorder: Should we be using Third Wave Therapies?. <i>Alcohol and Alcoholism</i> , 2019 , 54, 159-166	3.5	21
53	Cue Exposure Therapy for Alcohol Use Disorders: What Can Be Learned from Exposure Therapy for Anxiety Disorders?. <i>Substance Use and Misuse</i> , 2019 , 54, 2053-2063	2.2	10
52	Evidence-based models of care for the treatment of alcohol use disorder in primary health care settings: protocol for systematic review. <i>Systematic Reviews</i> , 2019 , 8, 275	3	2
51	Psychosocial interventions for people with both severe mental illness and substance misuse. <i>The Cochrane Library</i> , 2019 , 12, CD001088	5.2	11
50	Executive Functioning Moderates Responses to Appetitive Cues: A Study in Severe Alcohol Use Disorder and Alcoholic Liver Disease. <i>Alcohol and Alcoholism</i> , 2019 , 54, 38-46	3.5	7

49	A Review of Baclofen Overdoses in Australia: Calls to a Poisons Information Centre and a Case Series. <i>Alcohol and Alcoholism</i> , 2019 , 54, 73-78	3.5	9
48	Translating Evidence-Based Practice for Managing Comorbid Substance Use and Mental Illness Using a Multimodal Training Package. <i>Journal of Dual Diagnosis</i> , 2018 , 14, 111-119	2.4	7
47	Characteristics of Suicide Attempters and Ideators in a Clinical Sample of Substance Users. <i>Substance Use and Misuse</i> , 2018 , 53, 1811-1818	2.2	1
46	Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. <i>British Journal of Psychiatry</i> , 2018 , 212, 362-369	5.4	55
45	Biased and less sensitive: A gamified approach to delay discounting in heroin addiction. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2018 , 40, 139-150	2.1	13
44	Moderation of baclofen response by a GABA receptor polymorphism: results from the BacALD randomized controlled trial. <i>Addiction</i> , 2018 , 113, 2205-2213	4.6	15
43	Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2018 , 28, 795-806	12.3	98
42	N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 667-675	5.9	10
41	Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study). <i>Trials</i> , 2018 , 19, 443	2.8	4
40	Neurometabolite Levels in Alcohol Use Disorder Patients During Baclofen Treatment and Prediction of Relapse to Heavy Drinking. <i>Frontiers in Psychiatry</i> , 2018 , 9, 412	5	7
39	Psychostimulant-related health service demand in an inner-city hospital, 2012-2015. <i>Public Health Research and Practice</i> , 2018 , 28,	5.1	1
38	Intolerance of uncertainty and conditioned place preference in opioid addiction. <i>PeerJ</i> , 2018 , 6, e4775	3.1	6
37	The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. <i>Frontiers in Psychiatry</i> , 2018 , 9, 708	5	28
36	Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. <i>Lancet Psychiatry</i> , 2018 , 5, 957-960	23.3	60
35	Baclofen Response in Alcohol Dependent Patients Concurrently Receiving Antidepressants: Secondary Analysis From the BacALD Study. <i>Frontiers in Psychiatry</i> , 2018 , 9, 576	5	5
34	Pharmacotherapy for Alcohol Use Disorder in the Context of Liver Disease. <i>Current Addiction Reports</i> , 2018 , 5, 287-296	3.9	5
33	Socioeconomic and geographic disparities in access to pharmacotherapy for alcohol dependence. <i>Journal of Substance Abuse Treatment</i> , 2017 , 74, 23-25	4.2	14
32	Pharmacotherapeutic agents in the treatment of methamphetamine dependence. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 563-578	5.9	54

31	Reward and punishment-based compound cue learning and generalization in opiate dependency. <i>Experimental Brain Research</i> , 2017 , 235, 3153-3162	2.3	2
30	Learning and generalization from reward and punishment in opioid addiction. <i>Behavioural Brain Research</i> , 2017 , 317, 122-131	3.4	16
29	A Mobile Text Message Intervention to Reduce Repeat Suicidal Episodes: Design and Development of Reconnecting After a Suicide Attempt (RAFT). <i>JMIR Mental Health</i> , 2017 , 4, e56	6	16
28	Alcohol use disorders in Australia. <i>Internal Medicine Journal</i> , 2016 , 46, 1259-1268	1.6	12
27	Is Specialized Integrated Treatment for Comorbid Anxiety, Depression and Alcohol Dependence Better than Treatment as Usual in a Public Hospital Setting?. <i>Alcohol and Alcoholism</i> , 2016 , 51, 402-9	3.5	25
26	The impact of alcohol pharmacotherapies on public health in Australia is limited by low prescribing rates. <i>Public Health Research and Practice</i> , 2016 , 26,	5.1	4
25	National trends in alcohol pharmacotherapy: Findings from an Australian claims database. <i>Drug and Alcohol Dependence</i> , 2016 , 166, 254-7	4.9	29
24	Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety. <i>Alcohol and Alcoholism</i> , 2014 , 49, 654-60	3.5	69
23	The efficacy of an opportunistic cognitive behavioral intervention package (OCB) on substance use and comorbid suicide risk: a multisite randomized controlled trial. <i>Journal of Consulting and Clinical Psychology</i> , 2014 , 82, 130-40	6.5	24
22	Psychosocial interventions for people with both severe mental illness and substance misuse. <i>Schizophrenia Bulletin</i> , 2014 , 40, 18-20	1.3	26
21	Integrated care for comorbid alcohol dependence and anxiety and/or depressive disorder: study protocol for an assessor-blind, randomized controlled trial. <i>Addiction Science & Clinical Practice</i> , 2013 , 8, 19	4.1	10
20	The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. <i>Contemporary Clinical Trials</i> , 2013 , 36, 348-55 ^{2.3}	2.3	25
19	Psychosocial interventions for people with both severe mental illness and substance misuse. <i>The Cochrane Library</i> , 2013 , CD001088	5.2	82
18	Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial. <i>Substance Abuse and Rehabilitation</i> , 2012 , 3, 43-7	5.5	2
17	Some new directions for research on psychological interventions for comorbid anxiety and substance use disorders. <i>Drug and Alcohol Review</i> , 2010 , 29, 518-24	3.2	27
16	Clinical predictors of outcome from an Australian pharmacological relapse prevention trial. <i>Alcohol and Alcoholism</i> , 2010 , 45, 520-6	3.5	9
15	Expectancy in double-blind placebo-controlled trials: an example from alcohol dependence. <i>Psychotherapy and Psychosomatics</i> , 2009 , 78, 167-71	9.4	24
14	Sample bias from different recruitment strategies in a randomised controlled trial for alcohol dependence. <i>Drug and Alcohol Review</i> , 2009 , 28, 222-9	3.2	7

13	Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?. <i>Addiction</i> , 2008 , 103, 953-9	4.6	51
12	Issues with recruitment to randomised controlled trials in the drug and alcohol field: a literature review and Australian case study. <i>Drug and Alcohol Review</i> , 2008 , 27, 115-22	3.2	29
11	Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. <i>Addiction</i> , 2006 , 101, 1451-62	4.6	122
10	Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005 , 29, 648-57	5.5	55
9	Preexposure to MDMA ("Ecstasy") delays acquisition but facilitates MDMA-induced reinstatement of amphetamine self-administration behavior in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2004 , 79, 331-42	3.9	17
8	Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA ("Ecstasy") in rats. <i>Neuropharmacology</i> , 2004 , 46, 954-65	5.5	48
7	The consequences of beer consumption in rats: acute anxiolytic and ataxic effects and withdrawal-induced anxiety. <i>Psychopharmacology</i> , 2003 , 166, 51-60	4.7	39
6	Increased anxiety and "depressive" symptoms months after MDMA ("ecstasy") in rats: drug-induced hyperthermia does not predict long-term outcomes. <i>Psychopharmacology</i> , 2003 , 168, 465-74	4.7	71
5	Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. <i>European Journal of Pharmacology</i> , 2003 , 482, 339-41	5.3	55
4	Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. <i>European Journal of Pharmacology</i> , 2002 , 446, 89-96	5.3	78
3	Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("ecstasy"). <i>European Journal of Pharmacology</i> , 2001 , 433, 91-9	5.3	98
2	(+/-)-3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) increases social interaction in rats. <i>European Journal of Pharmacology</i> , 2000 , 408, 41-9	5.3	83
1	Implementation of a multi-modal training program for the management of comorbid mental disorders in drug and alcohol settings: Pathways to Comorbidity Care (PCC)		1